伴随诊断:监管框架,挑战和未来方向的概述
Harshada Kadam1, Amisha Vora1, Sanjay Sharma1
1Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's, NMIMS, Deemed to be University, Vile Parle West, Mumbai, Maharashtra 400056, India.
伴随性诊断 (CDx) 在精准医学中至关重要,扩展到瘤学之外. 像人工智能和NGS这样的先进技术正在克服监管和实施障碍,以获得更广泛的临床应用.
科学领域:
- 生物标志物发现和伴随诊断 (CDx)
- 精准医学在医疗保健中的应用.
背景情况:
- 伴随诊断 (CDx) 通过识别可能从特定治疗中受益的患者子组来弥合诊断和治疗.
- 最初专注于瘤学,CDx应用正在扩展到心脏病学,神经学,传染病和罕见疾病.
研究的目的:
- 审查CDx与美国,欧盟和日本的监管框架的共同开发.
- 突出CDx临床实施的挑战和新兴技术的影响.
主要方法:
- 分析美国,欧洲和日本的监管框架.
- 审查在CDx开发中集成下一代测序 (NGS),液体活检和人工智能 (AI) 等先进技术.
主要成果:
- 存在监管标准,但由于批准途径,分类,技术转让和经济因素的变化,瓶仍然存在.
- 下一代测序 (NGS) 和液体活检正在重塑CDx框架,解决现有的挑战.
- 人工智能 (AI) 在加快生物标志物发现,临床试验设计,患者获取和治疗反应监测方面显示出潜力.
结论:
- 集成NGS,液体活检和AI等先进技术对于克服CDx实施障碍至关重要.
- 人工智能可以通过分析复杂的数据集来加速监管决策,提高CDx的适应性.
- 这些技术进步正在推动CDx的演变,在全球范围内扩大精准医学的范围.
更多相关视频
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
07:43Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices
Published on: July 14, 2023
相关概念视频
Drug Regulation
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Preclinical Development: Overview
Drug Products: Biologics, Biosimilars and Interchangeables
Drug Control Governance: Regulatory Bodies and Their Impact
Therapeutic Drug Monitoring: Overview and Classification
